Business Wire

ShiftLeft to Present at No Hat Conference 2021

17.11.2021 11:00:00 EET | Business Wire | Press release

Share

ShiftLeft, Inc., an innovator in automated application security testing, today announced that its Chief Scientist, Fabian Yamaguchi, and Security Research Engineer, Claudiu-Vlad Ursache, will give a presentation focused on Ghidra2cpg at the No Hat Conference in Bergamo, Italy on November 20, 2021. The No Hat 2021 is a security conference organized to bring together specialists, professionals and hobbyists operating in the field of computer security and privacy.

Event Details:

Who: Fabian Yamaguchi, Chief Scientist and Claudiu-Vlad Ursache, Security Research Engineer, ShiftLeft
What: Virtual Session: Presentation on Ghidra2cpg: From graph queries to vulnerabilities in binary code
When: Saturday, November 20, 2021, 11:15am – 12:00pm CET
Where: Centro Congressi Giovanni XXIII - Bergamo, Italy

For more information, visit: https://www.nohat.it/program

Session Abstract - Ghidra2cpg: From graph queries to vulnerabilities in binary code

Uncovering bugs in source code is hard enough as it is, but when all you have is a binary, the importance of tooling becomes undeniable. Disassemblers such as IDA Pro, Ghidra, BinaryNinja or Radare2 provide a strong foundation for an investigation but are designed primarily to assist in what remains a manual investigation. This leaves room for partial automations that make the discovery process less painful.

Fabian and Claudiu were looking to design a search tool for binary code that allows them to uncover instances of programming patterns linked to vulnerabilities - at scale and for multiple major instruction sets. In this talk, they will present ghidra2cpg, an extension for the open-source code mining platform Joern that enables it to process binary code. Together, Joern and ghidra2cpg enable you to quickly uncover the attack surface, search for variants of known vulnerabilities, and gather information interactively using a query language.

In this session they will show how to write queries for the system that describe bugs in source code and introduce corresponding queries for binary code, highlighting what's harder and what is easier to describe when looking at the machine code directly. They will also be looking at modern consumer-grade router firmware and may drop a zero-day or two in the process.

About Fabian Yamaguchi

Fabian is Chief Scientist at ShiftLeft Inc and an Associate Professor Extraordinary at Stellenbosch University. He has over 15 years of experience in the security domain, where he has worked as a security consultant and researcher, focusing on manual and automated vulnerability discovery. Throughout his work, he has identified previously unknown vulnerabilities in popular system components and applications such as the Microsoft Windows kernel, the Linux kernel, the Squid proxy server, and the VLC media player. He has presented his findings and techniques at both major industry conferences such as BlackHat USA, DefCon, First, and CCC, and renowned academic security conferences such as ACSAC, Security and Privacy, and CCS. He holds a master’s degree in computer engineering from Technical University Berlin, as well as a PhD in computer science from the University of Goettingen.

About Claudiu-Vlad Ursache

Claudiu-Vlad Ursache is a Security Research Engineer at ShiftLeft, having recently entered cybersecurity after a decade of writing software. In his day-to-day job he builds static analysis tools and his current research focuses on IoT firmware.

About ShiftLeft

ShiftLeft enables software developers and application security teams to radically reduce the attackability of their applications by providing near-instantaneous security feedback on software code during every pull request. By analyzing application context and data flows in near real-time with industry leading accuracy, ShiftLeft empowers developers and appsec team to find and fix the most serious vulnerabilities faster. Using its patented graph analysis that combines code attributes and analyzes actual attack paths based on real application architecture, ShiftLeft’s platform scans for attack context and pathways typical of modern applications, across APIs, OSS, internal microservices and first-party business logic code, and then provides detailed guidance on risk remediation within existing development workflows and tooling. ShiftLeft CORE, a unified code security platform, combines the company’s flagship NextGen Static Analysis (NG SAST), Intelligent Software Composition Analysis (SCA), and contextual security training through ShiftLeft Educate to provide developers and application security teams the fastest, most accurate, most relevant, and easiest to use automated application security and code analysis platform.

Backed by Bain Capital Ventures, Mayfield, Thomvest Ventures, and SineWave Ventures, ShiftLeft is based in Santa Clara, CA. To learn how ShiftLeft keeps AppSec in sync with the rapid pace of DevOps, see https://www.shiftleft.io/.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

PR:
Corinna Krueger
ShiftLeft
ckrueger@shiftleft.io

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Yubico Appoints Poupak Modirassari Enbom as Chief Marketing Officer to Accelerate Global Momentum and Drive Market Leadership30.3.2026 16:00:00 EEST | Press release

Yubico (NASDAQ STOCKHOLM: YUBICO), the creator of the most secure passkeys and a leading provider of hardware authentication security keys, today announced the appointment of Poupak Enbom as Chief Marketing Officer (CMO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330278027/en/ Enbom joins Yubico at a pivotal moment as organizations worldwide accelerate the shift to phishing-resistant authentication and modern identity security in the age of AI. “We’re excited to welcome Poupak to Yubico,” said Jerrod Chong, acting chief executive officer, Yubico. “As the threat landscape evolves with AI-driven attacks and increasing automation, organizations are rethinking how they secure digital identities of both humans and AI agents at scale. She brings a unique combination of technical depth, global leadership, and customer-first mindset that will help us continue to expand our impact and support our customers and partners around

HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 15:00:00 EEST | Press release

HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate

Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 15:00:00 EEST | Press release

The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 500 million AGR uranium pellets and 222,000 AGR grids – which is equivalent to burning over 685 tonnes of coal, avoiding the emission of nearly 3 billion tonnes of CO2. Sp

Biocytogen Grants Taisho Pharmaceutical a License to its RenNano ® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 14:00:00 EEST | Press release

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro

Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 14:00:00 EEST | Press release

Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye